Fig. 1 Normal distribution of 18F-choline 2.2 11C-Acetate Acetate is absorbed by cells and converted into acetyl-CoA. In this form, it can be involved into two different metabolic pathways: either anabolic…
Reference n Inclusion criteria Randomization Definition of biochemical recurrence Median follow-up Biochemical progression-free survival (bNED) Overall survival Thompson et al. (2009), SWOG 8794 431 pT3 pN0 ± involved SM 60–64 Gy versus “wait…
Fig. 1 Dose distribution with an IMRT plan for salvage RT of the prostatic fossa, prescribed dose 66 Gy, 7 beams (XIO®, Elekta). Pink prostatic fossa, white clinical target volume, orange planning target volume, yellow bladder,…
Fig. 1 Axial dose distribution of prostate bed 7-field IMRT a with and b without an endorectal balloon In order to be well protected against too small clinical target volume, it…
(1) D1, D2, and D3 are isoeffective total doses, e.g., doses which cause 50 % of local tumor control (TCD-50); d1, d2, and d3 are the respective doses per fraction; α/ß…
Study Year of publication TNM 2002 Number of patients Androgen suppression therapy External irradiation Effect of overall survival Androgen suppression + radiotherapy versus radiotherapy alone (a) Adjuuvant (+/– concomittant) androgen suppression EORTC…
© Springer-Verlag Berlin Heidelberg 2014Hans Geinitz, Mack Roach III and Nicholas van As (eds.)Radiotherapy in Prostate CancerMedical Radiology10.1007/174_2014_1025 Treatment of Clinically Involved Lymph Nodes Arne Grün1 (1) Department for Radiation Oncology and Cyberknife Cente, Charité –…
© Springer-Verlag Berlin Heidelberg 2014Hans Geinitz, Mack Roach III and Nicholas van As (eds.)Radiotherapy in Prostate CancerMedical Radiology10.1007/174_2013_949 Prophylactic Treatment of the Pelvic Lymphatics: Contra Pascal Pommier1 (1) Radiotherapy Department, Centre Léon Bérard, 28 Rue Laënnec,…
First author Study design Key findings Asbell et al. (1988) and Hanks et al. (1991) Eligible patients (pts) had A2 (occult disease >3 + chips & poorly differentiated) and Stage B without clinical…
CT Rectum (Dose in cGy/fx) Bladder (Dose in cGy/fx) Femoral heads (Dose in cGy/fx) Diagnostic multidetector CT 1.74 1.83 4.05 kV CBCT 1.70 1.73 3.14 MVCT 1.05 1.04 1.02 2…
